Lucy Day
Vice President, HR & Finance at Anacor Pharmaceuticals - Palo Alto, California, United States
Lucy Day's Colleagues at Anacor Pharmaceuticals
Lucy Day's Contact Details
["6505437500","6507390700","6505437660","16466168639","16505437575","2025573506","946085104500761","8326367517","113857184973023"]
Anacor Pharmaceuticals
Lucy Day's Company Details
Anacor is a biopharmaceutical company focused on discovering, developing and commercializing novel small-molecule therapeutics derived from its boron chemistry platform. Anacor has discovered and is developing five clinical compounds, including its three lead programs: AN2690, a topical antifungal for the treatment of onychomycosis; AN2728, a topical anti-inflammatory PDE-4 inhibitor for the treatment of psoriasis; and GSK 2251052, or GSK '052 (formerly referred to as AN3365), a systemic antibiotic for the treatment of infections caused by Gram-negative bacteria, which has been licensed to GlaxoSmithKline under the companies' research and development agreement. In addition, Anacor is developing AN2718 as a topical antifungal product candidate for the treatment of onychomycosis and skin fungal infections, and AN2898 as a topical anti-inflammatory product candidate for the treatment of psoriasis and atopic dermatitis.